135 related articles for article (PubMed ID: 7690317)
1. Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation.
Olivera DL; Kaplan JM; Newman-Tarr T; Ruggieri EV; Badger AM
Clin Immunol Immunopathol; 1993 Sep; 68(3):357-62. PubMed ID: 7690317
[TBL] [Abstract][Full Text] [Related]
2. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells.
Pockley AG; Williams S; Reid SD; Bowles MJ
Biochem Soc Trans; 1995 Nov; 23(4):615S. PubMed ID: 8654800
[No Abstract] [Full Text] [Related]
3. Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent.
Kaplan JM; Badger AM; Ruggieri EV; Olivera DL; Newman-Tarr T; Bugelski PJ
J Clin Lab Immunol; 1991 Dec; 36(4):49-58. PubMed ID: 1668843
[TBL] [Abstract][Full Text] [Related]
4. Modes of action of FK506, cyclosporin A, and rapamycin.
Morris R
Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
[No Abstract] [Full Text] [Related]
5. Opposing effects of rapamycin and cyclosporin A on activation-induced Ca(2+) release.
Almawi WY; Assi JW; Chudzik DM; Lazarovits AI
Eur J Pharmacol; 1999 Sep; 381(1):51-6. PubMed ID: 10528133
[TBL] [Abstract][Full Text] [Related]
6. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture.
Wera S; Zheng L; Hooghe-Peters EL; Belayew A; Martial JA; Velkeniers B
Endocr Res; 1995 Aug; 21(3):623-33. PubMed ID: 7588431
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
Hatfield SM; Mynderse JS; Roehm NW
J Pharmacol Exp Ther; 1992 Jun; 261(3):970-6. PubMed ID: 1376361
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions.
Kahan BD
J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S222-7. PubMed ID: 1379841
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro.
Barten MJ; Gummert JF; van Gelder T; Shorthouse R; Morris RE
J Immunol Methods; 2001 Jul; 253(1-2):95-112. PubMed ID: 11384672
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin's inhibition of thymocyte proliferation, unlike that of cyclosporin A or prednisolone, is not associated with cytotoxicity.
Bansbach CC; Wancio D; Caccese RG; Shen CF; Sehgal SN
Ann N Y Acad Sci; 1993 Jun; 685():114-6. PubMed ID: 8363214
[No Abstract] [Full Text] [Related]
12. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line.
Schwaninger M; Blume R; Oetjen E; Knepel W
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):541-5. PubMed ID: 7509460
[TBL] [Abstract][Full Text] [Related]
13. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.
Wicker LS; Boltz RC; Matt V; Nichols EA; Peterson LB; Sigal NH
Eur J Immunol; 1990 Oct; 20(10):2277-83. PubMed ID: 1700753
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Bierer BE
Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
[No Abstract] [Full Text] [Related]
15. The actions of cyclosporin A and FK506 on T-lymphocyte activation.
Mattila PS
Biochem Soc Trans; 1996 Feb; 24(1):45-9. PubMed ID: 8674715
[No Abstract] [Full Text] [Related]
16. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth.
Iwabuchi T; Maruyama T; Sei Y; Adachi K
J Dermatol Sci; 1995 Jan; 9(1):64-9. PubMed ID: 7537082
[TBL] [Abstract][Full Text] [Related]
17. Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control.
Furuke K; Nakamura H; Hori T; Iwata S; Maekawa N; Inamoto T; Yamaoka Y; Yodoi J
Int Immunol; 1995 Jun; 7(6):985-93. PubMed ID: 7577807
[TBL] [Abstract][Full Text] [Related]
18. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity.
Bundick RV; Craggs RI; Holness E
Clin Exp Immunol; 1995 Mar; 99(3):467-72. PubMed ID: 7533681
[TBL] [Abstract][Full Text] [Related]
19. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells.
Ogawa T; Tokuda M; Tomizawa K; Matsui H; Itano T; Konishi R; Nagahata S; Hatase O
Biochem Biophys Res Commun; 1998 Aug; 249(1):226-30. PubMed ID: 9705862
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin.
Teutsch M; Higer M; Wang D; Wortis HW
Int Immunol; 1995 Mar; 7(3):381-92. PubMed ID: 7540861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
